Take as Directed: Improving Adherence With Oral Anticancer Agents

Please note that this activity is hosted by Medscape. In order to register and complete this activity, you will need to log in using a Medscape account. If you are not already a registered Medscape user, you will be given the option to sign up for a free account.

 

Ann H. Partridge, MD, MPH; R. Donald Harvey, PharmD; Anne E. Kelly, MSN, NP; Mark J. Ratain, MD

 

CME/CE Released: 07/27/2012; Valid for credit through 07/27/2013

Acknowledgement of Commercial Support

Supported in part by educational grants from Novartis, Celgene, and Pfizer, Inc.

 

This activity is intended for oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with cancer as well as cancer survivors.

The goal of this activity is to improve communication between members of the cancer care team and patients about adherence with oral anticancer regimens.

Upon completion of this activity, participants will be able to:

1. Outline the frequency and causes of patient nonadherence with oral anticancer treatment regimens.
2.  Discuss the consequences of nonadherence on costs and patient outcomes
3. Summarize clinical studies that have assessed the impact of patient nonadherence with oral anticancer regimens on patient outcomes in the hematology-oncology setting
4. Identify effective strategies for improving patient adherence with oral anticancer therapies
5. Describe effective communication and counseling skills and strategies to improve patients' adherence with oral anticancer therapies
6. Explain how the multidisciplinary cancer care team of oncologists, oncology nurses, and pharmacists can educate and counsel patients, families, and caregivers about the importance of adherence with oral anticancer agents

 

Faculty and Disclosures

The Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, Medscape and the Association of the Community Cancer Centers adhere to the ACCME Standards for Commercial Support. It is the policy of the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a potential conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

 

 

INVESTIGATIONAL AND/OR OFF-LABEL USE OF COMMERCIAL PRODUCTS AND DEVICES

The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

 

Ann H. Partridge, MD, MPH

Associate Professor of Medicine, Harvard Medical School; Director, Adult Cancer Survivorship Program and Program for Young Women With Breast Cancer, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, Massachusetts

 

Disclosure: Ann H. Partridge, MD, MPH, has disclosed that she has no relevant financial relationships.

Dr Partridge does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Partridge does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

 

R. Donald Harvey, PharmD

Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine; Director, Phase 1 Clinical Trials Section, Winship Cancer Institute at Emory University, Atlanta, Georgia

 

Disclosure: R. Donald Harvey, PharmD, has disclosed that he has no relevant financial relationships.

Dr Harvey does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Harvey does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

 

Anne E. Kelly, MSN, NP

Oncology Nurse Practitioner, Women’s Cancer Breast Oncology Program, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, Massachusetts

 

Disclosure: Anne E. Kelly, MSN, NP, has disclosed that she has no relevant financial relationships.

Ms Kelly does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Kelly does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

 

Mark J. Ratain, MD

Leon O. Jacobson Professor of Medicine; Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, Comprehensive Cancer Center; University of Chicago, Division of Biological Sciences, Chicago, Illinois

 

Disclosure: Mark J. Ratain, MD, has disclosed the following relevant financial relationships:
Served as an expert witness or consultant for: Mylan Laboratories Inc; Teva Pharmaceuticals.

Dr Ratain disclosed that there may be discussions of the following use of products and/or devices in the out-of-label context within this educational activity: Products: lapatinib, nilotinib, erlotinib, pazopanib, abiraterone. Investigational or off-label use: potential use of food to improve bioavailability, reduce dose and cost.

Dr Ratain does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

 

Margie Miller

Group Scientific Director, Medscape, LLC

Disclosure: Margie Miller has disclosed that she has no relevant financial relationships.

 

Carol Cadmus

Senior Clinical Editor, Medscape, LLC

Disclosure: Carol Cadmus has disclosed that she has no relevant financial relationships.

 

Jeanne Chapin

Associate Medical Editor, Medscape, LLC

Disclosure: Jeanne Chapin has disclosed that she has no relevant financial relationships.

 

Mila Kostic

Director, Continuing Medical Education, Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, Philadelphia, Pennsylvania

Disclosure: Mila Kostic has disclosed that she has no relevant financial relationships.

 

Michael Schoen, PhD

Outreach Projects Coordinator, Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, Philadelphia, Pennsylvania

Disclosure: Michael Schoen has disclosed that he has no relevant financial relationships.

 

Zalman Agus, MD

Associate Dean for Continuing Medical Education, Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, Philadelphia, Pennsylvania

Zalman Agus, MD, has disclosed that he has no relevant financial relationships

 

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosure: Nafeez Zawahir, MD, has disclosed that he has no relevant financial relationships.

 

Laurie E. Scudder, DNP, NP

Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

Disclosure: Laurie E. Scudder, DNP, NP, has disclosed that she has no relevant financial relationships.

 

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

1. Read the target audience, learning objectives, and author disclosures.
2. Study the educational content online or printed out.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

 

Credits Available

 

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

 

 

Accreditation Statements

For Physicians

The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.00 contact hour(s) of continuing nursing education for RNs and APNs; 1.00 contact hours are in the area of pharmacology.

Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.

 

 

For Pharmacists

Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) (Universal Activity Number 0461-9999-12-069-H01-P)

 

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net

 

Hardware/Software Requirements

To access activities, users will need:

• A computer with an Internet connection.
• Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
• Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback.
• Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.